Nov 23, 2021

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in multiple myeloma. Featuring perspectives from Drs Noopur Raje and Saad Zafar Usmani, including the following topics:

• Introduction
• Front-Line Treatment for Transplant-Ineligible Patients; Incorporation of CAR T-Cell Therapy — Dr Choksi
• Up-Front Management of Multiple Myeloma in Young Patients with Adverse Cytogenetics Chalk Talk — Dr Raje
• Efficacy and Tolerability of Subcutaneous versus IV Daratumumab in Patients with Multiple Myeloma Chalk Talk — Dr Usmani (Part 1)
• Substitution of Isatuximab for Daratumumab; Role of Transplant; Role of Minimal Residual Disease — Dr Kumar
• Nonresearch Role of Venetoclax for Patients with R/R Multiple Myeloma and t(11;14) or Bcl-2 Overexpression Chalk Talk — Dr Usmani (Part 2)
• Case: A man in his mid-60s with relapsed/refractory multiple myeloma with t(4:14) and del(17p) — Dr Usmani
• Comment on Dr Usmani’s 64-Year-Old Man: High-Risk Cytogenetics — Paul G Richardson, MD and Peter Voorhees, MD
• Comment on Dr Usmani’s 64-Year-Old Man: CAR T-Cell Therapy — Drs Richardson and Voorhees
• CAR T-Cell Therapy Investigational Strategies Chalk Talk — Dr Raje
• Investigational Bispecific Antibodies for R/R Multiple Myeloma Chalk Talk — Dr Usmani

CME information and select publications